STATEMENT RE EPIZYME

28 June 2022

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE EPIZYME

Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company") notes the announcement released yesterday by Ipsen ("IPN") regarding the definitive agreement pursuant to which Ipsen will acquire Epizyme Inc ("Epizyme") (the "Transaction"). The Company has a US$110 million investment in a senior secured loan to Epizyme which would be prepaid upon the closing of the Transaction. The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the Company would be expected to receive between US$3 to US$7 million in prepayment and make-whole fees.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END